0N4A Stock Overview
Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Vivesto AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.31 |
| 52 Week High | SEK 0.49 |
| 52 Week Low | SEK 0.21 |
| Beta | 0.40 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -89.55% |
| 5 Year Change | -94.72% |
| Change since IPO | -97.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0N4A | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -0.8% |
| 1Y | n/a | -16.8% | 9.2% |
Return vs Industry: Insufficient data to determine how 0N4A performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0N4A performed against the UK Market.
Price Volatility
| 0N4A volatility | |
|---|---|
| 0N4A Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0N4A has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0N4A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 6 | Erik Kinnman | www.vivesto.com |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto AB Fundamentals Summary
| 0N4A fundamental statistics | |
|---|---|
| Market cap | SEK 159.80m |
| Earnings (TTM) | -SEK 116.77m |
| Revenue (TTM) | SEK 6.61m |
24.2x
P/S Ratio-1.4x
P/E RatioIs 0N4A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0N4A income statement (TTM) | |
|---|---|
| Revenue | SEK 6.61m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 6.61m |
| Other Expenses | SEK 123.38m |
| Earnings | -SEK 116.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -0.22 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,766.05% |
| Debt/Equity Ratio | 0% |
How did 0N4A perform over the long term?
See historical performance and comparison